Arrowpoint Investment Partners Singapore Pte. Ltd. Acquires Shares of 4,053 Charles River Laboratories International, Inc. $CRL

Arrowpoint Investment Partners Singapore Pte. Ltd. acquired a new stake in Charles River Laboratories International, Inc. (NYSE:CRL) during the 4th quarter, HoldingsChannel.com reports. The institutional investor acquired 4,053 shares of the medical research company’s stock, valued at approximately $808,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Vise Technologies Inc. acquired a new position in shares of Charles River Laboratories International in the fourth quarter valued at $297,000. State of Wyoming increased its holdings in shares of Charles River Laboratories International by 60.3% in the fourth quarter. State of Wyoming now owns 3,606 shares of the medical research company’s stock valued at $719,000 after purchasing an additional 1,357 shares during the last quarter. 1492 Capital Management LLC acquired a new position in shares of Charles River Laboratories International in the fourth quarter valued at $1,209,000. CIBC Asset Management Inc increased its holdings in shares of Charles River Laboratories International by 70.0% in the fourth quarter. CIBC Asset Management Inc now owns 10,993 shares of the medical research company’s stock valued at $2,193,000 after purchasing an additional 4,526 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its holdings in shares of Charles River Laboratories International by 32.8% in the fourth quarter. Goldman Sachs Group Inc. now owns 317,570 shares of the medical research company’s stock valued at $63,349,000 after purchasing an additional 78,358 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have commented on CRL. Wall Street Zen downgraded shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Saturday, February 21st. Mizuho set a $192.00 target price on shares of Charles River Laboratories International in a research report on Friday, May 8th. Weiss Ratings raised shares of Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 29th. JPMorgan Chase & Co. reduced their target price on Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating on the stock in a report on Monday, April 13th. Finally, Barclays boosted their price target on Charles River Laboratories International from $210.00 to $220.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. Eleven equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $208.50.

Charles River Laboratories International Price Performance

Shares of NYSE:CRL opened at $185.65 on Friday. The company has a market cap of $8.94 billion, a price-to-earnings ratio of -49.37, a PEG ratio of 2.06 and a beta of 1.46. The company has a debt-to-equity ratio of 0.90, a current ratio of 1.36 and a quick ratio of 1.03. The firm has a 50 day simple moving average of $171.05 and a 200 day simple moving average of $181.57. Charles River Laboratories International, Inc. has a one year low of $140.78 and a one year high of $228.88.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Thursday, May 7th. The medical research company reported $2.06 earnings per share for the quarter, beating the consensus estimate of $1.96 by $0.10. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.The company had revenue of $995.83 million for the quarter, compared to the consensus estimate of $977.46 million. During the same quarter last year, the business posted $2.34 EPS. Charles River Laboratories International’s revenue for the quarter was up 1.2% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. Research analysts predict that Charles River Laboratories International, Inc. will post 11.04 earnings per share for the current fiscal year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.